טוען...
The Antitumor Drug LB-100 is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active Site Catalytic Metals in PPP5C
LB-100 is an experimental cancer-therapeutic with cytotoxic activity against cancer cells in culture and antitumor activity in animals. The first Phase I trial (NCT01837667) evaluating LB-100 recently concluded that safety and efficacy parameters are favorable for further clinical testing. Although...
שמור ב:
| הוצא לאור ב: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6397705/ https://ncbi.nlm.nih.gov/pubmed/30679389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-1143 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|